Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

RJ, Mayer; Cutsem E, Van; A, Falcone; T, Yoshino; R, Garcia-Carbonero; N, Mizunuma; K, Yamazaki; Y, Shimada; J, Tabernero; Y, Komatsu; A, Sobrero; E, Boucher; M, Peeters; B, Tran; HJ, Lenz; A, Zaniboni; H, Hochster; JM, Cleary; H, Prenen; F, Benedetti; H, Mizuguchi; L, Makris; M, Ito; A, Ohtsu

doi:10.1056/nejmoa1414325

Public

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Shared by NobleBlocks on May 1, 2015 • 12:00 AM UTC

Authors:

Mayer RJ

Van Cutsem E

Falcone A

Abstract

Background Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-1...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!